Theravance Biopharma TBPH Business Segments — Income Tax Expense Benefit

Similar metrics at other companies

POWISingle Reportable — Income Tax Expense Benefit

$620K-43.4%

MMSISingle Reportable — Income Tax Expense Benefit

$12.55M+60.7%

MCRISingle Reportable — Income Tax Expense Benefit

-$7.95M-37.8%

PAYOSingle Reportable — Income Tax Expense Benefit

$9.64M+34.1%

NSSCSingle Reportable — Income Tax Expense Benefit

$206K-89.1%

CBRLSingle Reportable — Income Tax Expense Benefit

$7.66M+384%

Questions, answered.

What is Theravance Biopharma's business segments — income tax expense benefit?

Theravance Biopharma (TBPH) reported business segments — income tax expense benefit of -$1.54M in Q1 2026.

How has Theravance Biopharma's business segments — income tax expense benefit changed year-over-year?

Theravance Biopharma's business segments — income tax expense benefit decreased by 175.0% year-over-year, from -$559K to -$1.54M.

What is the long-term trend for Theravance Biopharma's business segments — income tax expense benefit?

Over 2 years (2023 to 2025), Theravance Biopharma's business segments — income tax expense benefit has grown at a 98.5% compound annual growth rate (CAGR), from $5.92M to $23.35M.

What does business segments — income tax expense benefit mean?

This reflects the provision for income taxes or the recognition of tax benefits attributable to the segment's financial results. It is essential for calculating the segment's net contribution to the company's after-tax earnings and understanding the tax implications of its operational performance.